Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088797 | 0.84 | PIK3CA (0.62) | KMT2ACDK2DAPK3JAK2PRKD3 | |
| SCHEMBL15185772 | 0.83 | PLK1 (0.52) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL3951217 | 0.81 | LMNA (0.53) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL24507552 | 0.81 | ABL1 (0.62) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL27111928 | 0.81 | CDK2 (0.55) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL30847380 | 0.81 | CDK2 (0.55) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL14088796 | 0.81 | AURKA (0.72) | CDK2CDK4MAPK8CLK2DYRK1A | |
| SCHEMBL20004013 | 0.81 | PIK3CG (0.56) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL84004 | 0.81 | CDK2 (0.54) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL14088798 | 0.80 | SYK (0.60) | SMN1; SMN2POLBNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | SMN1; SMN2 3581/4885POLB 2484/4885NPC1 4113/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | SMN1; SMN2 3793/4885POLB 2078/4885NPC1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.